Adaptive Biotechnologies (ADPT) Capital Expenditures (2018 - 2026)

Adaptive Biotechnologies has reported Capital Expenditures for 9 years, with the latest figure at $159000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 87.37% year-over-year to $159000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 81.72% YoY) and the FY2025 annual result came in at $3.0 million, up 132.08% from the prior year.
• Capital Expenditures fell to $159000.0 in Q1 2026 per ADPT's latest filing, from $636000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $5.4 million in Q3 2022 and troughed at -$12.1 million in Q4 2022.
• A 5-year average of $399941.2 and a median of $636000.0 in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 1782.35% in 2024, then jumped 833.92% in 2025.
• Over 5 years, Capital Expenditures stood at -$12.1 million in 2022, then jumped by 94.86% to -$621000.0 in 2023, then soared by 300.64% to $1.2 million in 2024, then slumped by 48.96% to $636000.0 in 2025, then slumped by 75.0% to $159000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $159000.0, $636000.0, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.